These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. Kretz CA, Cuddy KK, Stafford AR, Fredenburgh JC, Roberts R, Weitz JI. Thromb Haemost; 2010 Jan; 103(1):83-93. PubMed ID: 20062917 [Abstract] [Full Text] [Related]
24. Highly sulfated dermatan sulfate from the skin of the ray Raja montagui: anticoagulant activity and mechanism of action. Ben Mansour M, Dhahri M, Hassine M, Ajzenberg N, Venisse L, Ollivier V, Chaubet F, Jandrot-Perrus M, Maaroufi RM. Comp Biochem Physiol B Biochem Mol Biol; 2010 Jul; 156(3):206-15. PubMed ID: 20363356 [Abstract] [Full Text] [Related]
25. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate. Cosmi B, Agnelli G, Young E, Hirsh J, Weitz J. Thromb Haemost; 1993 Sep 01; 70(3):443-7. PubMed ID: 8259546 [Abstract] [Full Text] [Related]
26. Further studies on the mechanism for the antithrombotic effects of naroparcil, an orally active thiozyloside compound. Masson P, Theveniaux J, Coup D, Grégoire T, Vaillot M, Dupouy D, Sié P, Boneu B, Millet J. Thromb Haemost; 1999 Jun 01; 81(6):945-50. PubMed ID: 10404773 [Abstract] [Full Text] [Related]
31. Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid P component: comparison with other plasma and platelet proteins. Williams EC, Huppert BJ, Asakura S. J Lab Clin Med; 1992 Jul 01; 120(1):159-67. PubMed ID: 1377216 [Abstract] [Full Text] [Related]
32. Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis. Rau JC, Mitchell JW, Fortenberry YM, Church FC. Semin Thromb Hemost; 2011 Jun 01; 37(4):339-48. PubMed ID: 21805439 [Abstract] [Full Text] [Related]
33. Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II. Sarilla S, Habib SY, Kravtsov DV, Matafonov A, Gailani D, Verhamme IM. J Biol Chem; 2010 Mar 12; 285(11):8278-89. PubMed ID: 20053992 [Abstract] [Full Text] [Related]
34. Altering heparin cofactor II at VAL439 (P6) either impairs inhibition of thrombin or confers elastase resistance. Cunningham MA, Bhakta V, Sheffield WP. Thromb Haemost; 2002 Jul 12; 88(1):89-97. PubMed ID: 12152684 [Abstract] [Full Text] [Related]
35. A survey of the clinical experience with dermatan sulfate. Gianese F, Lucchelli PE. Semin Thromb Hemost; 1991 Jul 12; 17 Suppl 2():199-204. PubMed ID: 1948090 [No Abstract] [Full Text] [Related]
36. Investigating serpin-enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II. Sutherland JS, Bhakta V, Sheffield WP. Thromb Res; 2006 Jul 12; 117(4):447-61. PubMed ID: 15869786 [Abstract] [Full Text] [Related]
37. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II. Buchanan MR, Liao P, Smith LJ, Ofosu FA. Thromb Res; 1994 Jun 01; 74(5):463-75. PubMed ID: 8085247 [Abstract] [Full Text] [Related]
38. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II. Liaw PC, Austin RC, Fredenburgh JC, Stafford AR, Weitz JI. J Biol Chem; 1999 Sep 24; 274(39):27597-604. PubMed ID: 10488098 [Abstract] [Full Text] [Related]